Local pro-inflammatory cytokine and nitric oxide responses are elevated in patients with pterygium

International Journal of Immunopathology and Pharmacology

Volumn 30, Issue 4, 2017, Pages 395-405

  Zidi, S ^a,b,c   Bediar Boulaneb, F ^d   Belguendouz, H ^b   Belkhelfa, M ^b   Medjeber, O ^b   Laouar, O ^d   Henchiri, C ^c   Touil Boukoffa, C ^b  

^a UNIVERSITY OF GUELMA   (Algeria)

^b UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^c BADJI MOKHTAR UNIVERSITY   (Algeria)

^d Centre Hospitalier Universitaire de Annaba   (Algeria)

Author keywords

cytokines; inflammation; NO synthase; pterygium

Indexed keywords

CD3 ANTIGEN; CD68 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; NITRIC OXIDE; PROTEIN BCL 2; BCL2 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; NOS2 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; LACRIMAL FLUID; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTERYGIUM; TISSUE INJURY; BLOOD; CONJUNCTIVA; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; CONJUNCTIVA; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MIDDLE AGED; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTO-ONCOGENE PROTEINS C-BCL-2; PTERYGIUM; TEARS;

EID: 85039859743     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/0394632017742505     Document Type: Article

References (48)

1. Chui J, Di Girolamo N, Wakefield D. (2008). The pathogenesis of pterygium: Current concepts and their therapeutic implications. Ocular Surface 6: 24–43.
2. Chui J, Coroneo MT, Tat LT. (2011) Ophthalmic pterygium: A stem cell disorder with premalignant features. American Journal of Pathology 178(2): 817–827.
3. Anguria P, Kitinya J, Ntuli S. (2014) The role of heredity in pterygium development. International Journal of Ophthalmology 7(3): 563–573.
4. Cárdenas-Cantú E, Zavala J, Valenzuela J. (2016). Molecular basis of pterygium development. Seminars in Ophthalmology 31(6): 567–583.
5. Yam JC, Kwok AK, (2014) Ultraviolet light and ocular diseases. International Ophthalmology 34(2): 383–400.
6. Nolan TM, DiGirolamo N, Sachdev NH. (2003) The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium. American Journal of Pathology 162(2): 567–574.
7. Di Girolamo N, Wakefield D, Coroneo MT, (2006) UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Investigative Ophthalmology & Visual Science 47(6): 2430–2437.
8. Awasthi A, Kuchroo VK, (2009) Th17 cells: From precursors to players in inflammation and infection. International Immunology 21(5): 489–498.
9. Mesquita D, Jr Cruvinel WM, Câmara NOS. (2009) Autoimmune diseases in the TH17 era. Brazilian Journal of Medical and Biological Research 42(6): 476–486.
10. Rafa H, Saoula H, Belkhelfa M. (2013) IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: Immunomodulatory effect of retinoic acid. Journal of Interferon & Cytokine Research 33(7): 355–368.
11. Benchabane S, Boudjelida A, Toumi R. (2016) A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren’s syndrome. International Journal of Immunopathology and Pharmacology 29(3): 386–397.
12. Brand S, (2009) Crohn’s disease: Th1, Th17 or both? The change of a paradigm: New immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 58: 1152–1167.
13. Soufli I, Toumi R, Rafa H. (2016) Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World Journal of Gastrointestinal Pharmacology and Therapeutics 7(3): 353–360.
14. Karthikeyan A, Patnala R, Jadhav SP. (2016) MicroRNAs: Key players in microglia and astrocyte mediated inflammation in CNS pathologies. Current Medicinal Chemistry 23(30): 3528–3546.
15. Tesmer LA, Lundy SK, Sarkar S. (2008) Th17 cells in human disease. Immunological Reviews 223: 87–113.
16. Zhou L, Ivanov II, Spolski R. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunology 8(9): 967–974.
17. Kolios G, Valatas V, Ward SG, (2004) Nitric oxide in inflammatory bowel disease: A universal messenger in an unsolved puzzle. Immunology 113(4): 427–437.
18. Rafa H, Benkhelifa S, Ait Younes S. (2017) All-trans retinoic acid modulates TLR4/NF-κB signaling pathway targeting TNF-α and nitric oxide synthase 2 expression in colonic mucosa during ulcerative colitis and colitis associated cancer. Mediators of Inflammation 2017; 2017: 7353252.
19. Belguendouz H, Messaoudène D, Lahmar K. (2011) Interferon-γ and nitric oxide production during Behçet uveitis: Immunomodulatory effect of interleukin-10. Journal of Interferon & Cytokine Research 31(9): 643–651.
20. Jones DT, Monroy D, Pflugfelder SC, (1997) A novel method of tear collection: Comparison of glass capillary micropipettes with porous polyester rods. Cornea 16(4): 450–458.
21. Touil-Boukoffa C, Bauvois B, Sancéau J. (1998) Production of nitric oxide (NO) in human hydatidosis: Relationship between nitrite production and interferon-gamma levels. Biochimie 80(8–9): 739–744.
22. Liu T, Liu Y, Xie L. (2013) Progress in the pathogenesis of pterygium. Current Eye Research 38(12): 1191–1197.
23. Kormanovski A, Parra F, Jarillo-Luna A. (2014) Oxidant/antioxidant state in tissue of primary and recurrent pterygium. BMC Ophthalmology 14: 149.
24. Ozdemir G, Inanc F, Kilinc M, (2005) Investigation of nitric oxide in pterygium. Canadian Journal of Ophthalmology 40: 743–746.
25. Balci M, Sahin S, Mutlu FM. (2011) Investigation of oxidative stress in pterygium tissue. Molecular Vision 17: 443–447.
26. Lee DH, Cho HJ, Kim JT. (2001) Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20(7): 738–742.
27. Kleinert H, Pautz A, Linker K. (2004) Regulation of the expression of inducible nitric oxide synthase. European Journal of Pharmacology 500(1–3): 255–266.
28. Siak JJK, Ng SL, Seet LF. (2011) The nuclear-factor kappaB pathway is activated in pterygium. Investigative Ophthalmology & Visual Science 52(1): 230–236.
29. Torres J, Enríquez-de-Salamanca A, Fernández I. (2011) Activation of MAPK signaling pathway and NF-κB activation in pterygium and ipsilateral pterygium-free conjunctival specimens. Investigative Ophthalmology & Visual Science 52: 5842–5852.
30. Napetschnig J, Wu H, (2013) Molecular basis of NF-κB signaling. Annual Review of Biophysics 42: 443–468.
31. Lee HS, Lee MS, Lee YJ. (2016) Chondrocyte-derived extracellular matrix suppresses pathogenesis of human pterygium epithelial cells by blocking the NF-κB signaling pathways. Molecular Vision 22: 1490–1502.
32. Chao SC, Hu DN, Roberts J. (2007) Inhibition effect of curcumin on UVB-induced secretion of pro-inflammatory cytokines from corneal limbus epithelial cells. International Journal of Ophthalmology 10(6): 827–833.
33. Josifovska N, Szabó DJ, Nagymihály R. (2017) Cultivation and characterization of pterygium as an ex vivo study model for disease and therapy. Contact Lens & Anterior Eye 40(5): 283–292.
34. Jabarin B, Solomon A, Amer R, (2016) Interleukin-17 and its correlation with vascular endothelial growth factor expression in ocular surface pathologies: A histologic study. European Journal of Ophthalmology 26(4): 283–286.
35. Tiong KI, Zahidin AZM, Sumugam SK. (2017) Evaluation of Interleukin-17 and Interleukin-23 in pterygium: Immunohistochemistry study. Asia-Pacific Journal of Ophthalmology 6: 403–406.
36. Fujino S, Andoh A, Bamba S. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1): 65–70.
37. Katz Y, Nadiv O, Beer Y, (2001) Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: A possible role as a ‘fine-tuning cytokine’ in inflammation processes. Arthritis & Rheumatism 44(9): 2176–2184.
38. Stockinger B, Veldhoen M, (2007) Differentiation and function of Th17 T cells. Current Opinion in Immunology 19(3): 281–286.
39. Korn T, Bettelli E, Gao W. (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448(7152): 484–487.
40. Korn T, Bettelli E, Oukka M. (2009) IL-17 and Th17 Cells. Annual Review of Immunology 27: 485–517.
41. Di Girolamo N, Kumar RK, Coroneo MT. (2002) UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Investigative Ophthalmology & Visual Science 43(11): 3430–3437.
42. Di Girolamo N, Chui J, Coroneo MT. (2004) Pathogenesis of pterygia: Role of cytokines, growth factors, and matrix metalloproteinases. Progress in Retinal and Eye Research 23: 195–228.
43. Di Girolamo N, McCluskey P, Lloyd A. (2000) Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Investigative Ophthalmology & Visual Science 41(3): 671–679.
44. Livezeanu C, Crăiţoiu MM, Mănescu R. (2011) Angiogenesis in the pathogenesis of pterygium. Romanian Journal of Morphology and Embryology 52(3): 837–844.
45. Tan DT, Tang WY, Liu YP. (2000) Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. British Journal of Ophthalmology 84(2): 212–216.
46. Liang K, Jiang Z, Ding BQ. (2011) Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva. Molecular Vision 17: 1687–1693.
47. Szabó C, Ischiropoulos H, Radi R, (2007) Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nature Reviews Drug Discovery 6(8): 662–680.
48. Bianchi E, Scarinci F, Grande C. (2012) Immunohistochemical profile of VEGF, TGF-β and PGE2 in human pterygium and normal conjunctiva: Experimental study and review of the literature. International Journal of Immunopathology and Pharmacology 25(3): 607–615.